< Back to companies

Esya's DNA probes can ratiometrically quantify ions within endocytic organelles such as Endosomes & Lysosomes, for diseases such as COVID-19, Lysosomal Storage Disorders & Alzheimer's Disease. We are a precision biomarker company providing groundbreaking molecular insights to facilitate drug discovery, diagnostics, and personalized medicine, by profiling ion signatures within key organelles. By chemically profiling various biological markers, such as lysosomal ion signatures, our technologies can help decode the underpinnings of a number of different diseases, as well as test potential drug treatments and therapies.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2017
Website
www.esyalabs.com/

Categories

Precision MedicineBiomarker MonitoringDrug DiscoveryDiagnostics

Disease Areas

Technologies

BiomarkersMolecular DiagnosticsDrug Discovery
Only accessible to MedStartr community members. Join now

What do you think of Esya Labs?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now